AU9052091A - Vaccines based on hepatitis b surface antigen - Google Patents

Vaccines based on hepatitis b surface antigen

Info

Publication number
AU9052091A
AU9052091A AU90520/91A AU9052091A AU9052091A AU 9052091 A AU9052091 A AU 9052091A AU 90520/91 A AU90520/91 A AU 90520/91A AU 9052091 A AU9052091 A AU 9052091A AU 9052091 A AU9052091 A AU 9052091A
Authority
AU
Australia
Prior art keywords
hepatitis
surface antigen
vaccines based
vaccines
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU90520/91A
Other languages
English (en)
Inventor
Michelle Baijot
Jean-Paul Prieels
Frans Van Wijnendaele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU9052091(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027623A external-priority patent/GB9027623D0/en
Priority claimed from GB919105993A external-priority patent/GB9105993D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of AU9052091A publication Critical patent/AU9052091A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU90520/91A 1990-12-20 1991-12-16 Vaccines based on hepatitis b surface antigen Abandoned AU9052091A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9027623 1990-12-20
GB909027623A GB9027623D0 (en) 1990-12-20 1990-12-20 Novel compounds
GB9105993 1991-03-21
GB919105993A GB9105993D0 (en) 1991-03-21 1991-03-21 Vaccines

Publications (1)

Publication Number Publication Date
AU9052091A true AU9052091A (en) 1992-07-22

Family

ID=26298142

Family Applications (1)

Application Number Title Priority Date Filing Date
AU90520/91A Abandoned AU9052091A (en) 1990-12-20 1991-12-16 Vaccines based on hepatitis b surface antigen

Country Status (4)

Country Link
EP (1) EP0563091A1 (de)
JP (1) JPH06503821A (de)
AU (1) AU9052091A (de)
WO (1) WO1992011291A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767755B2 (en) * 1992-03-27 2003-11-20 Smithkline Beecham Biologicals (Sa) Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid_A

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0835663B1 (de) * 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
IT1256575B (it) * 1992-12-10 1995-12-11 Cesalpino Andrea Fond Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili.
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
HU219056B (hu) * 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
KR970061917A (ko) * 1996-02-29 1997-09-12 성재갑 헤르페스 심플렉스 바이러스 당단백질의 항원 결정부위와 b형 간염 바이러스의 표면 항원 단백질의 융합단백질
DE69933200T2 (de) * 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
ATE412434T1 (de) 1998-11-30 2008-11-15 Cytos Biotechnology Ag Molekulare anordnung von allergenen, verfahren zur deren herstellung und deren verwendung
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
CA2487849A1 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
DK1524994T3 (da) 2002-07-19 2011-08-15 Cytos Biotechnology Ag Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ZA200707413B (en) 2005-03-18 2009-01-28 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
EP1736538A1 (de) 2005-06-21 2006-12-27 Cytos Biotechnology AG Prozess für die preparative Reinigung von Virus-ähnlichen Partikeln (VLPs)
US20110027220A1 (en) 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子
ES2427994T3 (es) 2006-06-12 2013-11-05 Cytos Biotechnology Ag Procesos para empaquetar oligonucleótidos en partículas de tipo viral de bacteriófagos de ARN
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
EP2865389A1 (de) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 Peptid-Impfstoff
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
EP2942061A3 (de) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
US9506041B2 (en) 2012-03-26 2016-11-29 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Delivery of packaged RNA to mammalian cells
SG10201811190SA (en) 2013-12-16 2019-01-30 Us Health Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US20220088188A1 (en) * 2018-12-24 2022-03-24 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
CA3155202A1 (en) 2019-10-23 2021-04-29 Arthur M. Krieg Synthetic rig-i-like receptor agonists
JP2023529925A (ja) 2020-06-12 2023-07-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナノ粒子ワクチンを使用する細菌免疫化
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
GB8903313D0 (en) * 1989-02-14 1989-04-05 Wellcome Found Conjugates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767755B2 (en) * 1992-03-27 2003-11-20 Smithkline Beecham Biologicals (Sa) Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid_A

Also Published As

Publication number Publication date
JPH06503821A (ja) 1994-04-28
EP0563091A1 (de) 1993-10-06
WO1992011291A1 (en) 1992-07-09

Similar Documents

Publication Publication Date Title
AU9052091A (en) Vaccines based on hepatitis b surface antigen
AU709406C (en) Combined vaccines comprising hepatitis B surface antigen and other antigens
HUP9901901A3 (en) Vaccines against hepatitis c
GB9001766D0 (en) Vaccines
AU4325089A (en) Viral vaccines
AU4878096A (en) Hepatitis b vaccine
AU634518B2 (en) Hepatitis B core antigen conjugates
AU5679394A (en) Hepatitis b virus vaccines
AU1522792A (en) Multiple hepatitis b virus surface proteins which form particles
AU7713387A (en) Hepatitis vaccine
AU8537091A (en) Membrane-derived antiflea vaccines
AU7909391A (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
AU5873094A (en) Multivalent ab1 antibodies as vaccines
GB9014652D0 (en) Antigen
AU3269793A (en) Method for obtaining recombinant surface antigen of hepatitis B, antigen and vaccine based on it
AU645641B2 (en) Babesial protease antigen
IE880242L (en) Hepatitis b virus antigens.
GB9020799D0 (en) Viral vaccines
GB9006097D0 (en) Vaccines
GB9011358D0 (en) Vaccines
GB9522485D0 (en) Hepatitis b surface antigen variants
HU0400424D0 (en) Hepatitis virus vaccines
IE880458L (en) Virus antigen
AU3931197A (en) Vaccines and antigenic conjugates
SI0810877T1 (en) Hepatitis b vaccine